Investigation of IL-17A Serum Levels in Patients with Nonmelanoma Skin Cancer

Table 1

Clinicopathologic characteristics of NMSC patients and their respective IL-17A serum levels in each subgroup.

Variables		Number (valid percent)	IL-17A serum level (pg/ml)^1	value
Gender	Male	45 (75.0%)	5.64 (3.20–6.05)	0.357
	Female	15 (25.0%)	3.20 (3.00–6.02)
Age	Over 50	55 (92.0%)	5.69 (3.20–6.05)	0.286
	Below 50	5 (8.0%)	3.20 (3.10–6.02)
Type of NMSC	SCC^2	40 (66.7%)	5.95 (3.20–6.013)	0.793
	BCC^3	20 (33.3%)	5.86 (3.81–6.12)
Tumor site	Sun-exposed	54 (93.10%)	5.82 (5.62–6.02)	0.124
	Nonsun-exposed	4 (6.90%)	5.44 (3.20–5.90)
Lesions	Multiple	8 (13.3%)	5.85 (3.85–6.04)	0.667
	Single	52 (86.6%)	5.79 (3.20–6.16)
Tumor size	≥4 cm	20 (33.3%)	6.02 (4.89–7.15)	0.769
	<4 cm	40 (66.7%)	5.89 (5.83–6.02)

¹Median (1^st–3^rd interquartile); ²squamous cell carcinoma; ³basal cell carcinoma.